Carecubes Raises $6.5 Million Series A as Demand Grows for Rapid-Deployment Isolation Units

New updates have been reported about Carecubes.

Carecubes has secured $6.5 million in Series A financing to scale its FDA 510(k)-cleared ISTARI isolation units, positioning the company to expand deployment across health systems facing persistent infectious disease pressures. The funding, backed by senior leaders from Oscar Health, Aetna, Medtronic, Cardinal Health, and major public-sector institutions, will support broader commercialization, manufacturing, and go-to-market execution.

The company reports that hospitals, clinics, and emergency response systems in more than 36 communities across 13 states and territories have already purchased its units, including major systems such as Bellevue Hospital of NYC Health+Hospitals, Providence Sacred Heart Medical Center, and Cooper University Health Care. This traction indicates early product-market fit for a solution that can be deployed in minutes to isolate pathogens, reduce PPE burden, free up negative-pressure rooms, and improve throughput while maintaining bedside care.

Led by CEO Alex Laskey, who previously founded and took Opower public, and co-founder Saul Griffith, a MacArthur “Genius Grant” recipient, Carecubes is positioned as an infrastructure-like platform for infectious disease response within healthcare facilities. The company’s governance and advisory bench includes former executives from Cardinal Health and SEIU, as well as a former White House Domestic Policy Council director, signaling a strategy that spans both health systems and government preparedness buyers.

The technology originated from funding by the Defense Advanced Research Projects Agency and has been further supported by the CDC and the Administration for Strategic Preparedness and Response, with development conducted alongside infectious disease experts at the University of Nebraska Medical Center. This combination of federal backing, clinical validation, and permanent FDA 510(k) authorization provides regulatory and credibility advantages as Carecubes targets broader U.S. and international adoption.

Manufacturing is based in Minnesota with key suppliers across North Carolina, Connecticut, California, and Ohio, creating a domestic supply chain capable of scaling for surge demand scenarios. For health systems, the units are intended to address structural gaps exposed by recent outbreaks, especially in rural and under-resourced settings where isolation capacity is limited and staffing is constrained.

Investors and advisors highlight the dual value proposition of improving provider safety and patient experience while offering a scalable, cost-conscious tool for outbreak management. For executives evaluating capital allocation, Carecubes’ units are positioned as an operational resilience asset that can mitigate the financial and clinical risks of airborne infections such as measles, RSV, and tuberculosis, and future emerging threats.

The company’s near-term focus appears to be deepening penetration in hospital networks and regional coalitions, with an eye toward government preparedness contracts that can provide recurring and programmatic demand. If Carecubes can convert early adoption into standardized infection-control infrastructure, it stands to become a key vendor in the infectious disease response ecosystem and a potential consolidator or strategic target in the health safety technology space.